Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Amie Phinney
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,300
- Beta
- 1.35
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.64
Financials
Net Income
$-2.97MEBITDA
$-1.41MFree Cash Flow
$-1.59M-344263.3%EPS (diluted)
$-0.05Shares Outstanding (diluted)
59.03M+69.6%Operating Expenses
$1.41MCash & Debt
$2.96MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-4.00M | $-0.05 |
| 2024 | $0.00 | $-13.19M | $-0.30 |
| 2023 | $0.00 | $-6.76M | $-0.17 |
| 2022 | $0.00 | $-7.34M | $-0.20 |
| 2021 | $0.00 | $-2.86M | $-0.11 |
| 2020 | $0.00 | $-673.2K | $-0.02 |
| 2019 | $0.00 | $-1.9K | $-0.00 |
Valuation
DTCFFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (6)
- Newsnewsfilecorp.com·7d ago·Neutral
…oints Finance Executive Sherry Aulin to Its Board of Directors Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Aud…
View source ↗ - Newsnewsfilecorp.com·7d ago·Neutral
…s Corporate Update as Company Executes on Strategic Priorities Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholde…
View source ↗ - Newsnewsfilecorp.com·28d ago·Neutral
…ess and Outlines Strategic Priorities in Letter to Shareholders Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, st…
View source ↗ - Newsnewsfilecorp.com·31d ago·Negative
Defence Therapeutics Provides Updates on Sharing Agreement Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and Febru…
View source ↗ - Newsnewsfilecorp.com·36d ago·Neutral
…eutical Development Strategy with Alpha and Beta-Emitter Programs Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. Th…
View source ↗ - Newsnewsfilecorp.com·50d ago·Negative
… Chief Operating Officer and Head of Radiopharmaceutical Programs Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthen…
View source ↗
Congress trades
No disclosed congressional trades in DTCFF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.